Free Trial

BridgeBio Pharma (BBIO) Stock Forecast & Price Target

$27.12
+0.23 (+0.86%)
(As of 07/12/2024 ET)

BridgeBio Pharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$47.21
74.09% Upside
High Forecast$70.00
Average Forecast$47.21
Low Forecast$33.00
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$47.21$47.62$47.17$26.63
Forecasted Upside74.09% Upside54.24% Upside54.10% Upside73.53% Upside
Get BridgeBio Pharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.

BBIO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BBIO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BridgeBio Pharma Stock vs. The Competition

TypeBridgeBio PharmaMedical CompaniesS&P 500
Consensus Rating Score
2.92
2.71
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside74.09% Upside994.16% Upside9.19% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/1/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$70.00 ➝ $70.00+176.68%
6/25/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$50.00 ➝ $42.00+77.51%
6/20/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$43.00 ➝ $43.00+55.74%
5/28/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$51.00 ➝ $47.00+68.22%
5/14/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$50.00+75.44%
3/21/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$45.00+57.18%
3/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$35.00 ➝ $45.00+58.28%
3/5/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$60.00 ➝ $53.00+63.81%
2/23/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$42.00 ➝ $46.00+34.58%
1/31/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$37.00+2.52%
12/8/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$58.00+72.57%
7/18/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$29.00 ➝ $50.00+56.05%
7/18/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$32.00 ➝ $42.00+31.09%
7/17/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$24.00 ➝ $33.00+3.00%
4/13/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$25.00 ➝ $27.00+77.87%
2/6/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
1/23/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$23.00 ➝ $19.00+123.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:15 PM ET.

BBIO Forecast - Frequently Asked Questions

What is BridgeBio Pharma's forecast for 2024?

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for BridgeBio Pharma is $47.21, with a high forecast of $70.00 and a low forecast of $33.00.

Should I buy or sell BridgeBio Pharma stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BridgeBio Pharma in the last twelve months. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BBIO shares.

Does BridgeBio Pharma's stock price have much upside?

According to analysts, BridgeBio Pharma's stock has a predicted upside of 56.52% based on their 12-month stock forecasts.

Has BridgeBio Pharma been upgraded by Wall Street analysts recently?

Over the previous 90 days, BridgeBio Pharma's stock had 1 upgrade by analysts.

What analysts cover BridgeBio Pharma?

BridgeBio Pharma has been rated by research analysts at Bank of America, Cantor Fitzgerald, Evercore ISI, HC Wainwright, and UBS Group in the past 90 days.

Do Wall Street analysts like BridgeBio Pharma more than its competitors?

Analysts like BridgeBio Pharma more than other "medical" companies. The consensus rating score for BridgeBio Pharma is 2.92 while the average consensus rating score for "medical" companies is 2.71. Learn more on how BBIO compares to other companies.


This page (NASDAQ:BBIO) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners